Compare the Decrease in Visceral Adipose Tissue in People with Obesity and Prediabetes vs Obesity and Type 2 Diabetes Treated with Liraglutide

Obesity is considered a global pandemic. Visceral adipose tissue (VAT) presents greater lipolysis, lower insulin sensitivity and greater metabolic alterations. Liraglutide is a GLP-1 analogue that improves the expression of GLUT 4R, MAP kinases, decreases TGF-β, reactivates the PPAR-ɣ pathway and decreases chronic inflammation. Objectives: To compare the difference in the determination of visceral adipose tissue in people with obesity and type 2 diabetes vs obesity and prediabetes treated with liraglutide. Methods: A quasi-experimental, analytical, prolective, non-randomized, non-blind study was carried out over a period of 6 months in a third-level center. A total of 36 participants were divided into 2 arms; G1 (Obesity and prediabetes) and G2 (Obesity and type 2 diabetes) for 6 months. Inclusion criteria: men and women ≥18 years, with type 2 diabetes, prediabetes and obesity. Exclusion criteria: GFR <60 thousand/min/1.73m2sc, elevated transaminases (> 5 times ULN) and use of non-weight-modifying antidiabetic drugs. Conclusion: No statistically significant difference was found in the decrease of visceral adipose tissue when comparing G1 (OB and PD) vs. G2 (OB and T2D). When comparing intragroups in G2 (OB and DT2), greater weight loss was found [(-3.78 kg; p0.012)Vs.(-3.78 kg;p0.012)], waist circumference [(-3.9 cm;p0.049)Vs.(-3.09 cm;p0.017)], glucose [(-1.75 mmol/L; p0.002)Vs.(- 0.56 mmol/L; p0.002)], A1c% [(-1.15%;p0.001)Vs.(-0.5%; p0.000)].